Trial Profile
Combination therapy of immuno checkpoint inhibitors and radiosensitization treatment for metastatic melanoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Oct 2021
Price :
$35
*
At a glance
- Drugs Hyaluronic acid (Primary) ; Hydrogen peroxide (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 11 Oct 2018 Status changed from not yet recruiting to recruiting.
- 11 Apr 2017 New trial record